Loss of clumping factor B fibrinogen binding activity by Staphylococcus aureus involves cessation of transcription, shedding and cleavage by metalloprotease.
The fibrinogen-binding protein clumping factor B (ClfB) of Staphylococcus aureus is present on the surface of cells from the early exponential phase of growth in greater amounts than on cells from late exponential phase and is barely detectable on cells from stationary phase. Expression of a clfB-lacZ fusion indicated that transcription stopped before the end of exponential phase. Mutations in the global regulators agr and sar had no effect on clfB transcription. The loss of ClfB protein from cells in stationary phase was due to expression ending before cells stopped growing, combined with shedding of some of the protein into the growth medium and dilution of those molecules remaining on the cell surface during the two to three cell division events leading to stationary phase. Two forms of the protein occurred on the cell surface, the smaller of which was generated by loss of a domain from the N terminus. The proportion of the smaller form increased as the cultures grew. The metalloprotease aureolysin was shown to be responsible for cleavage of ClfB. Cleavage was inhibited by EDTA and o-phenanthroline and did not occur in an aureolysin-deficient mutant. Purified aureolysin promoted cleavage of cell surface-located ClfB as well as the recombinant A domain of ClfB. Cleavage was detected at two sites, one located between residues Ser(197) and Leu(198) and the other between Ala(199) and Val(200). The truncated form of ClfB did not bind fibrinogen.
McAleese
F M
FM
Microbiology Department, Moyne Institute for Preventive Medicine, Trinity College, Dublin 2, Ireland.
Walsh
E J
EJ
Sieprawska
M
M
Potempa
J
J
Foster
T J
TJ
D018829:Adhesins, Bacterial / Q000378:metabolism / Q000502:physiology*; D000409:Alanine / Q000737:chemistry; D001665:Binding Sites; D015139:Blotting, Southern; D015153:Blotting, Western; D003030:Coagulase / Q000378:metabolism* / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005340:Fibrinogen / Q000378:metabolism*; D017930:Genes, Reporter; D005838:Genotype; D007930:Leucine / Q000737:chemistry; D008666:Metalloendopeptidases / Q000378:metabolism; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010618:Phenanthrolines / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D012694:Serine / Q000737:chemistry; D013211:Staphylococcus aureus / Q000378:metabolism*; D013997:Time Factors; D014158:Transcription, Genetic; D014633:Valine / Q000737:chemistry; D001616:beta-Galactosidase / Q000378:metabolism
D018829:Adhesins, Bacterial; D003030:Coagulase; D010618:Phenanthrolines; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; C434058:clfB protein, Staphylococcus aureus; D012694:Serine; D005340:Fibrinogen; D004492:Edetic Acid; D001616:beta-Galactosidase; D008666:Metalloendopeptidases; D007930:Leucine; D014633:Valine; D000409:Alanine; C025205:1,10-phenanthroline